Cancer Cell

Papers
(The H4-Index of Cancer Cell is 106. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Accelerated approvals: Early-phase success or premature authorization?2132
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton600
KIT as a therapeutic target in neuroendocrine prostate cancer577
TAMing immunity through an unexpected source537
Characterization of the generic mutant p53-rescue compounds in a broad range of assays414
A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture406
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer405
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition368
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients353
Long-range cholinergic input promotes glioblastoma progression351
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer341
Diet-microbiome interactions in cancer335
Lymphoma accelerates T cell and tissue aging298
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer294
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations288
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling285
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas264
Spatial profiling technologies illuminate the tumor microenvironment264
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer256
T cell dynamism and immune-related adverse events252
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron246
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer245
The aging lung microenvironment awakens melanoma metastases244
Cancer vaccines242
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses241
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion237
Bacteria in metastatic sites: Unveiling hidden players in cancer progression236
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma236
B cell heterogeneity in cancer comes of age226
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer220
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation219
A holistic view of cancer218
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer217
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target217
Challenges in neoantigen-directed therapeutics213
High endothelial venules in cancer: Regulation, function, and therapeutic implication211
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer211
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin208
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity200
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer199
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer198
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments196
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors196
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding195
Immunosensitivity cuts across mismatch repair status in colorectal cancer193
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells193
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?188
A genetic portrait of metastatic seeds in lung adenocarcinoma185
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts183
Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer179
Tumor organoid-originated biomarkers predict immune response to PD-1 blockade177
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation177
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma176
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors172
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma164
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy164
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression163
Challenges and opportunities for modeling aging and cancer161
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer160
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma156
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification154
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation153
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients149
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma149
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis147
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer144
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy144
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity143
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population141
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics140
Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes139
Dissecting bulk transcriptomes of diffuse large B cell lymphoma139
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions138
A path to translation: How 3D patient tumor avatars enable next generation precision oncology138
Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies137
ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy136
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma135
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1135
Immune determinants of the pre-metastatic niche133
Integrated proteogenomic characterization of glioblastoma evolution131
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness130
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers130
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells129
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment126
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma125
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD124
Midkine as a driver of age-related changes and increase in mammary tumorigenesis121
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells120
Tumor-infiltrating lymphocytes: A new hope120
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring118
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study117
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis117
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells116
GDF15 research from bench to bedside116
Tumors on different wavelengths115
Firing up neutrophil anti-tumor immunity with cocktails113
The winner takes it all: Competition drives clonal selection in gliomagenesis111
A circular RNA in neuroendocrine carcinomas110
Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma109
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma108
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma108
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy108
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers107
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma107
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma106
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer106
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment106
0.25175404548645